The Hill: U.S. pharmaceutical company Merck is partnering with research nonprofit IAVI to develop a coronavirus vaccine, with clinical trials beginning by the end of this year, the partners announced Tuesday.
IAVI and Merck will work together to develop and evaluate the vaccine which will use the technology that is the basis for Merck’s Ebola Zaire virus vaccine.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now